Skip to content
The Heather Cutler Foundation Back to the campaign

Media

Canadians are calling their health ministers about a pancreatic cancer drug they cannot get.

The Heather Cutler Foundation and Pancreatic Cancer Can't Wait have opened a free phone line that connects people in Canada to the federal Minister of Health and to their own provincial health minister, to ask for a path to daraxonrasib.

Media contact Christopher Cutler Founder and Executive Director, The Heather Cutler Foundation 1-855-754-5045, ext. 2 press@heathercutler.ca If there is no answer, leave your name, outlet, number and deadline.

The facts, with sources

The drug Daraxonrasib (brand name Rasonque) is a pill made by Revolution Medicines for pancreatic cancer that has spread, in adults who have already had one treatment. Source: European Medicines Agency
The trial result In the phase 3 trial of 500 patients, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. Source: U.S. Food and Drug Administration, August 26, 2026
Approved elsewhere United States: approved August 26, 2026. European Union: approved by the European Commission, November 2026. Sources: U.S. Food and Drug Administration; European Commission
Canada Not approved, with no decision and no public timeline. Revolution Medicines gave HCF no filing date on November 5, 2026. The FDA's published review says it worked with Health Canada on the U.S. review through Project Orbis. HCF has not been able to confirm whether an application has been filed in Canada. Daraxonrasib is not on Health Canada's list of submissions under review, current to September 30, 2026. Source: Revolution Medicines' reply to HCF, November 5, 2026; FDA review documents for daraxonrasib; Health Canada, Submissions Under Review list
The disease Pancreatic cancer is expected to be the third-leading cause of cancer death in Canada in 2026. Source: Canadian Cancer Society
The campaign so far The line opened on November 19, 2026. Call totals and the written replies we receive from offices will be posted here.

Facts last checked November 17, 2026. Approval status in the European Union and Canada updated November 20, 2026.

What the campaign asks for

  • The federal Minister of Health to name a lead on Canadian access and coordinate with the company, the provinces and the territories.
  • Provincial and territorial health ministers to name a lead and say whether interim or exceptional funding could be considered for eligible patients.
  • Revolution Medicines to say publicly whether it has applied to Health Canada, to apply if it has not, and to publish a clear access route for Canadian patients.

People you can speak with

Christopher Cutler, Founder and Executive Director, The Heather Cutler Foundation.

Salman Syed, founder of Pancreatic Cancer Can't Wait. To request an interview, email press@heathercutler.ca and we will pass it on.

Other spokespeople will be added here as they agree to speak.

Downloads

  • News release, November 19, 2026 (PDF)
  • Logos: on request from press@heathercutler.ca
  • Photos cleared for publication: on request from press@heathercutler.ca
  • Voice messages cleared for broadcast: on request from press@heathercutler.ca

About The Heather Cutler Foundation

The Heather Cutler Foundation is a registered Canadian charity (743014227 RR 0001) based in Mount Pearl, Newfoundland and Labrador. It works on pancreatic cancer education, patient support, and advocacy, and was founded in memory of Heather Cutler, RN.

About Pancreatic Cancer Can't Wait

Pancreatic Cancer Can't Wait is a patient-led campaign started by Salman Syed, who is living with metastatic pancreatic cancer. pancreaticcantwait.ca